UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 11, 2006

NEUROMETRIX, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction of Incorporation)

(781) 890-9989

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02                                             Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On January 11, 2006, William Laverack, Jr. notified NeuroMetrix, Inc. (the “Company”) that he was resigning as a director of the Company effective as of January 15, 2006.  Mr. Laverack had no disagreements with the Company on any matter relating to the Company’s operations, policies or practices.

The Board of Directors of the Company thanks Mr. Laverack for his dedicated service and valued contributions to the Company.

The Board of Directors of the Company appointed Allen J. Hinkle, M.D. to serve as a new member of the Board effective as of January 15, 2006.  Dr. Hinkle will serve as a Class I Director with a term expiring in 2008.  Initially, Dr. Hinkle will not be serving on any committees of the Board.

On January 17, 2006, the Company issued a press release regarding the appointment of Dr. Hinkle.  The full text of the press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

Item 9.01                                             Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is being furnished herewith:

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

3

EXHIBIT INDEX

4

Exhibit 99.1

NeuroMetrix Inc. Names Allen Hinkle, M.D., to its Board of Directors

WALTHAM, MA. January 17, 2006 – NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Allen Hinkle, M.D., has been named to the company’s board of directors effective January 15, 2006.

Dr. Hinkle is currently the Chief Medical Officer for Tufts Health Plan in Massachusetts where he is responsible for medical management programs and initiatives.

Prior to becoming the Chief Medical Officer of Tufts Health Plan, Dr. Hinkle was Vice President of health care quality, policy and innovations at Blue Cross Blue Shield of Massachusetts.  He was previously the Chief Medical Officer and Senior Vice President of Quality – Healthcare Management for Anthem Blue Cross Blue Shield of New Hampshire and Matthew Thornton Plan.  Dr. Hinkle has over 20 years of experience in the healthcare field and has demonstrated strong leadership and innovation throughout his distinguished career.  He has successfully focused his efforts on improving the quality of health care and implementing operational efficiencies.

Dr. Hinkle received his Bachelor of Science degree from the University of Massachusetts at Amherst and his medical degree from Albert Einstein College of Medicine in New York.  He is board certified in pediatrics and anesthesiology and is an Associate Professor of Anesthesiology and Pediatrics at Dartmouth Medical School.  He is also a Board member of the Massachusetts Health Quality Partners.

 “We feel that Allen is a tremendous addition to the NeuroMetrix board of directors.  He brings a strong base of knowledge and experience relevant to our emerging growth business at NeuroMetrix.   We look forward to Allen’s insights, guidance and analytical thinking as we continue to establish our neuropathy diagnostic solution as a standard of care and expand our business into new areas such as therapeutic products for neuropathies,” said Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix.

About NeuroMetrix

NeuroMetrix is a medical device company establishing a new standard of care through the design, development and sale of proprietary products used to diagnose neuropathies. Neuropathies are diseases of the peripheral nerves and parts of the spine that frequently are caused by or associated with diabetes, low back and leg pain and carpal tunnel syndrome, as well as other clinical disorders.  These clinical indications affect millions of patients in the United States. The NC-stat System, the Company’s neuropathy diagnostic system, has been on the market since May 1999 and is presently used in nearly 3,000 physician’s offices, clinics and other health care facilities in the United States. The Company holds issued utility patents covering a number of important aspects of the NC-stat System.

Contact: NeuroMetrix, Inc.

Brad Smith, 781-314-2741

Chief Financial Officer

NeuroMetrix.ir@NeuroMetrix.com